Most of these specialists prefer pegylated interferon for treatment of these patients: 54% of the Oncologists preferred pegylated interferon the remainder,46%, did not answer this question; 58% of the Hematological Oncologists selected pegylated interferon; and 70% of surgical oncologists preferred pegylated interferon.
Casi todos los especialistas se inclinan a usar interferón pegilado en estos pacientes. De los oncólogos, el 54% prefiere interferón pegilado y el resto 46% no contestó esta pregunta.